Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.48 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | MMP1 | P03956 | 1/20 | 0.46 |
| ▸ | MMP2 | P08253 | 1/20 | 0.46 |
| ▸ | MMP3 | P08254 | 1/20 | 0.46 |
| ▸ | MMP9 | P14780 | 1/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.46 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CHKA | P35790 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14506909 | 1.00 | TDP1 (0.57) | TDP1CYP1A2ALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL19046575 | 1.00 | TDP1 (0.57) | TDP1CYP1A2ALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL14034527 | 1.00 | TDP1 (0.57) | TDP1CYP1A2ALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL3438657 | 1.00 | TDP1 (0.57) | TDP1CYP1A2ALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL27023033 | 1.00 | TDP1 (0.57) | TDP1CYP1A2ALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL18228339 | 1.00 | TDP1 (0.57) | TDP1CYP1A2ALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL8053 | 1.00 | — | — | |
| SCHEMBL896298 | 1.00 | — | — | |
| SCHEMBL17901788 | 1.00 | TDP1 (0.57) | TDP1CYP1A2ALDH1A1KDM4ESMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL8522398 | 0.97 | TDP1 (0.55) | TDP1CYP1A2ALDH1A1KDM4ESMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 160 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230365561-A1 | BETA-LACTAMASE INHIBITORS AND THEIR PREPARATION | NINGXIA ACADEMY OF AGRICULTURE AND FORESTRY SCIENCES (CN) | 2023-11-16 | — | — | US | disclosed |
| WO-2023220572-A1 | PTPN2 INHIBITORS | NESS THERAPEUTICS, INC. (US) | 2023-11-16 | — | — | WO | disclosed |
| US-20230181535-A1 | UBIQUITIN-LIGASE INHIBITORS FOR THE TREATMENT OF CANCER | FUND PROFESOR NOVOA SANTOS (ES) | 2023-06-15 | — | — | US | disclosed |
| US-20230181535-A1 | UBIQUITIN-LIGASE INHIBITORS FOR THE TREATMENT OF CANCER | FUND PROFESOR NOVOA SANTOS (ES) | 2023-06-15 | — | — | US | disclosed |
| US-20230019032-A1 | BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2023-01-19 | — | — | US | disclosed |
| WO-2022135432-A1 | MACROCYCLIC HETEROCYCLIC COMPOUNDS AS EGFR INHIBITORS, AND USE THEREOF | 南京圣和药业股份有限公司 | 2022-06-30 | — | — | WO | disclosed |
| EP-3689875-B1 | USE OF TRIAZOLOPYRIMIDINE, TRIAZOLOPYRIDINE COMPOUNDS AND COMPOSITION THEREOF FOR TREATING PRC2-MEDIATED DISEASES | SHANGHAI INST MATERIA MEDICA CAS (CN) | 2021-10-13 | — | — | EP | disclosed |
| US-11001575-B1 | Benzolactam compounds as protein kinase inhibitors | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2021-05-11 | — | — | US | disclosed |
| EP-2813512-B1 | PEPTIDE-COMPOUND CYCLIZATION METHOD | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2021-03-31 | — | — | EP | disclosed |
| US-10858352-B2 | Pharmaceutical compounds | HEPTARES THERAPEUTICS LIMITED (GB) | 2020-12-08 | — | — | US | disclosed |
| EP-0654023-B1 | 5-(2-OXYPHENYL)-PYRROLE DERIVATIVES AS DOPAMINE D3 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1998-09-16 | — | — | EP | disclosed |
| CN-1184123-A | Organic optical component | MITSUI TOATSU CHEMICALS (JP) | 1998-06-10 | — | — | CN | disclosed |
| US-5523299-A | ADMINISTERING IN TREATMENT OF PSYCHOTIC DISORDERS | SMITHKLINE BEECHAM PLC (GB) | 1996-06-04 | — | — | US | disclosed |
| EP-0654023-A1 | 5-(2-OXYPHENYL)-PYRROLE DERIVATIVES AS DOPAMINE D3 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1995-05-24 | — | — | EP | disclosed |
| CN-1084169-A | New phenylpyrrole derivative and its production and use | SMITHKLINE BEECHAM PLC (GB) | 1994-03-23 | — | — | CN | disclosed |
| WO-1994003426-A1 | 5-(2-OXYPHENYL)-PYRROLE DERIVATIVES AS DOPAMINE D3 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1994-02-17 | — | — | WO | disclosed |
| US-4554252-A | SUBSTITUTED AMIDE | ESZAKMAGYARORSZAGI VEGYIMUVEK (HU) | 1985-11-19 | — | — | US | disclosed |
| US-4234484-A | FROM ALKOXYLATED CYCLIC AMIDES USING AS A CATALYST A QUATERNARY AMMONIUM OR ALKALI METAL SALT OF TETRAFLUOROBORIC OR HEXAFLUOROPHOSPHORIC ACID | HOECHST AKTIENGESELLSCHAFT (DE) | 1980-11-18 | — | — | US | disclosed |
| US-4149941-A | ELECTROLYTIC ALKOXYLATION | HOECHST AKTIENGESELLSCHAFT (DE) | 1979-04-17 | — | — | US | disclosed |
| US-4118500-A | Fungicidal alkoxy mono- and dialkoxy N-substituted cyclic amines | HOECHST AKTIENGESELLSCHAFT (DE) | 1978-10-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230019032-A1 | BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS | MAPK1, ALK, MAP3K1 | TDP1 884/4885CYP1A2 1393/4885ALDH1A1 1598/4885 |
| US-20230181535-A1 | UBIQUITIN-LIGASE INHIBITORS FOR THE TREATMENT OF CANCER | XIAP, UBQLN1, MDM2 | TDP1 1752/4885CYP1A2 4150/4885ALDH1A1 1206/4885 |
| US-20230365561-A1 | BETA-LACTAMASE INHIBITORS AND THEIR PREPARATION | MGAM, LCT, GANAB | TDP1 3367/4885CYP1A2 330/4885ALDH1A1 315/4885 |
| US-11001575-B1 | Benzolactam compounds as protein kinase inhibitors | MAPK1, ALK, MAP3K1 | TDP1 931/4885CYP1A2 1488/4885ALDH1A1 1601/4885 |
| US-10858352-B2 | Pharmaceutical compounds | CHRM1, CHRM2, CHRM4 | TDP1 2921/4885CYP1A2 312/4885ALDH1A1 2679/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.